HomeCompareDUSXF vs JNJ

DUSXF vs JNJ: Dividend Comparison 2026

DUSXF yields 1175.78% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DUSXF wins by $2.42M in total portfolio value
10 years
DUSXF
DUSXF
● Live price
1175.78%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.45M
Annual income
$14,216.47
Full DUSXF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — DUSXF vs JNJ

📍 DUSXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDUSXFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DUSXF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DUSXF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DUSXF
Annual income on $10K today (after 15% tax)
$99,941.21/yr
After 10yr DRIP, annual income (after tax)
$12,084.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, DUSXF beats the other by $8,098.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DUSXF + JNJ for your $10,000?

DUSXF: 50%JNJ: 50%
100% JNJ50/50100% DUSXF
Portfolio after 10yr
$1.24M
Annual income
$9,452.94/yr
Blended yield
0.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DUSXF
No analyst data
Altman Z
-0.2
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DUSXF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDUSXFJNJ
Forward yield1175.78%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$2.45M$30.3K
Annual income after 10y$14,216.47$4,689.40
Total dividends collected$1.64M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DUSXF vs JNJ ($10,000, DRIP)

YearDUSXF PortfolioDUSXF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$69,489$58,788.95$10,592$272.30+$58.9KDUSXF
2$265,250$190,896.36$11,289$357.73+$254.0KDUSXF
3$624,321$340,504.43$12,123$472.89+$612.2KDUSXF
4$1,042,533$374,509.30$13,141$629.86+$1.03MDUSXF
5$1,407,744$292,233.84$14,408$846.81+$1.39MDUSXF
6$1,690,682$184,395.63$16,021$1,151.60+$1.67MDUSXF
7$1,912,514$103,484.43$18,122$1,588.22+$1.89MDUSXF
8$2,101,092$54,702.10$20,930$2,228.20+$2.08MDUSXF
9$2,276,251$28,082.17$24,792$3,191.91+$2.25MDUSXF
10$2,449,805$14,216.47$30,274$4,689.40+$2.42MDUSXF

DUSXF vs JNJ: Complete Analysis 2026

DUSXFStock

Dustin Group AB (publ) provides online IT products and services in Nordic and Benelux regions. It operates through three segments: Small and Medium-Sized Businesses, Large Corporate and Public Sector, and Business to Consumer. The company offers hardware, software, and related services and solutions. It also acts as a strategic IT partner for small and medium-sized businesses, large sized businesses, and public sector and consumers. The company was founded in 1984 and is headquartered in Nacka Strand, Sweden.

Full DUSXF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DUSXF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DUSXF vs SCHDDUSXF vs JEPIDUSXF vs ODUSXF vs KODUSXF vs MAINDUSXF vs ABBVDUSXF vs MRKDUSXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.